

# Clinical Pharmacokinetics of Tacrolimus

Clinical Pharmacokinetics

29, 404-430

DOI: 10.2165/00003088-199529060-00003

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cyclosporin and Tacrolimus in Clinical Transplantation. <i>BioDrugs</i> , 1996, 5, 351-373.	0.7	19
2	Design principles for orally bioavailable drugs. <i>Drug Discovery Today</i> , 1996, 1, 179-189.	3.2	193
3	Autoimmune Enteropathy in a Pediatric Patient: Partial Response to Tacrolimus Therapy. <i>Clinical Pediatrics</i> , 1997, 36, 295-299.	0.4	13
4	Interactions Between Tacrolimus and Antimicrobial Agents. <i>Clinical Infectious Diseases</i> , 1997, 25, 1430-1440.	2.9	104
5	Immunosuppressive Agents in Clinical Trials Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 313, 283-288.	0.4	7
6	Tacrolimus. <i>Drugs</i> , 1997, 54, 925-975.	4.9	281
7	Clinically Significant Drug Interactions with New Immunosuppressive Agents. <i>Drug Safety</i> , 1997, 16, 267-278.	1.4	122
8	FK506 Prevents Induction of Rat Experimental Autoimmune Myasthenia Gravis. <i>Journal of Autoimmunity</i> , 1997, 10, 11-16.	3.0	33
9	Excretion of tacrolimus glucuronides in human bile. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1997, 22, 217-221.	0.6	13
10	Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 62, 41-49.	2.3	254
11	Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. <i>Pharmaceutical Research</i> , 1998, 15, 1609-1613.	1.7	70
12	Clinical pharmacology of combination disease-controlling (DCART/DMARD) therapy in rheumatoid arthritis. <i>Zeitschrift Fur Rheumatologie</i> , 1998, 57, 20-24.	0.5	1
13	Tacrolimus pharmacokinetics in BMT patients. <i>Bone Marrow Transplantation</i> , 1998, 21, 23-28.	1.3	38
14	Massive ingestion of tacrolimus in a young liver transplant patient. <i>Transplantation Proceedings</i> , 1998, 30, 4327-4329.	0.3	6
15	IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A. <i>Annual Review of Pharmacology and Toxicology</i> , 1998, 38, 389-430.	4.2	772
16	Comparison of Tacrolimus Absorption in Transplant Patients Receiving Continuous versus Interrupted Enteral Nutritional Feeding. <i>Annals of Pharmacotherapy</i> , 1998, 32, 633-636.	0.9	22
17	Hepatic Extraction of Tacrolimus in Rats with Experimental Liver Diseases.. <i>Biological and Pharmaceutical Bulletin</i> , 1998, 21, 610-614.	0.6	10
18	Analytical Validation of the PRO-Trac II ELISA for the Determination of Tacrolimus (FK506) in Whole Blood. <i>Clinical Chemistry</i> , 1999, 45, 1449-1458.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Bioequivalence of 1 and 5 mg Tacrolimus Capsules Using a Replicate Study Design. <i>Journal of Clinical Pharmacology</i> , 1999, 39, 1032-1037.	1.0	18
20	Therapeutic drug monitoring of immunosuppressant drugs. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 339-350.	1.1	65
21	P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. <i>Pharmaceutical Research</i> , 1999, 16, 1213-1218.	1.7	106
22	Effect of T-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. <i>Liver Transplantation</i> , 1999, 5, 101-106.	1.9	6
23	Optimum Use of Tacrolimus in the Prophylaxis of Graft Versus Host Disease. <i>BioDrugs</i> , 1999, 11, 343-358.	2.2	4
24	Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg. <i>Clinical Therapeutics</i> , 1999, 21, 2058-2064.	1.1	17
25	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. <i>Clinical Therapeutics</i> , 1999, 21, 1632-1652.	1.1	106
26	Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 51-53.	0.3	1
27	Immunosuppressant-Induced Nephropathy. <i>Drug Safety</i> , 1999, 21, 471-488.	1.4	96
28	Effects of Liver Disease on Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1999, 37, 399-431.	1.6	205
29	Advancing the art of immunosuppression with the science of pharmacology. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 255-262.	0.8	6
30	Therapeutic drug monitoring in solid-organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2000, 5, 330-335.	0.8	3
31	Coadministration of Tacrolimus and Mycophenolate Mofetil in Stable Kidney Transplant Patients: Pharmacokinetics and Tolerability. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 527-532.	1.0	34
32	Evaluation of microparticle enzyme immunoassay against HPLC-mass spectrometry for the determination of whole-blood tacrolimus in heart- and lung-transplant recipients. <i>Clinical Biochemistry</i> , 2000, 33, 557-562.	0.8	18
33	Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 531-541.	1.1	46
34	Tacrolimus: pharmacology and therapeutic uses in dermatology. <i>International Journal of Dermatology</i> , 2000, 39, 721-727.	0.5	31
35	Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. <i>Bone Marrow Transplantation</i> , 2000, 25, 449-451.	1.3	10
36	Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 98-103.	2.3	109

#	ARTICLE	IF	CITATIONS
37	Can Absolute Oral Bioavailability in Humans be Predicted from Animals? A Comparison of Allometry and Different Indirect Methods. <i>Drug Metabolism and Drug Interactions</i> , 2000, 16, 143-156.	0.3	27
38	Intracerebral Abscess Caused by <i>Nocardia otitidiscaviarum</i> in a Renal Transplant Patient â€” Cured by Evacuation plus Antibiotic Therapy. <i>Nephron</i> , 2000, 86, 79-83.	0.9	29
39	Renal Allograft Dysfunction Associated with Rifampinâ€”Tacrolimus Interaction. <i>Annals of Pharmacotherapy</i> , 2000, 34, 27-31.	0.9	90
40	FK506 and Cyclosporin A Enhance the Survival of Cultured and Grafted Rat Embryonic Dopamine Neurons. <i>Experimental Neurology</i> , 2000, 164, 94-101.	2.0	40
41	Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. <i>American Journal of Kidney Diseases</i> , 2000, 35, 660-666.	2.1	115
42	Drug Concentration Monitoring of Immunosuppressive Agents. <i>BioDrugs</i> , 2000, 14, 355-369.	2.2	15
43	Tacrolimus. <i>Drugs</i> , 2000, 59, 323-389.	4.9	266
44	Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy. <i>Clinical Pharmacokinetics</i> , 2001, 40, 63-71.	1.6	40
45	Comparative Clinical Pharmacokinetics of Tacrolimus in Paediatric and Adult Patients. <i>Clinical Pharmacokinetics</i> , 2001, 40, 283-295.	1.6	124
46	Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit. <i>Clinical Pharmacokinetics</i> , 2001, 40, 833-868.	1.6	123
47	Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. <i>Transplantation Proceedings</i> , 2001, 33, 1066-1068.	0.3	27
48	Pharmacokinetics of tacrolimus during the early phase after heart transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 2386-2389.	0.3	13
49	Optimal time for determination of blood tacrolimus level. <i>Transplantation Proceedings</i> , 2001, 33, 3164-3165.	0.3	7
50	THE EFFECT OF GUT METABOLISM ON TACROLIMUS BIOAVAILABILITY IN RENALTRANSPLANT RECIPIENTS <sup>1,2</sup> . <i>Transplantation</i> , 2001, 71, 1303-1307.	0.5	90
51	Effect of Ascites on Tacrolimus Disposition in a Liver Transplant Recipient. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 644-646.	1.0	6
52	Comparative Tacrolimus Pharmacokinetics: Normal versus Mildly Hepatically Impaired Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 628-635.	1.0	42
53	Clinical Utility of Monitoring Tacrolimus Blood Concentrations in Liver Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 542-551.	1.0	140
54	Effect of Low- and High-Fat Meals on Tacrolimus Absorption following 5 mg Single Oral Doses to Healthy Human Subjects. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 176-182.	1.0	112

#	ARTICLE	IF	CITATIONS
55	Effect of Time of Meal Consumption on Bioavailability of a Single Oral 5 mg Tacrolimus Dose. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 289-297.	1.0	82
56	Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2246-2249.	0.4	16
57	Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. <i>Pediatric Transplantation</i> , 2001, 5, 119-124.	0.5	19
58	Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 95-99.	0.8	40
59	Tacrolimus and diarrhea: Pathogenesis of altered metabolism. <i>Pediatric Transplantation</i> , 2001, 5, 75-79.	0.5	41
60	High trough levels of oral FK506 induced by loss of small intestine. <i>Pediatric Transplantation</i> , 2001, 5, 434-438.	0.5	14
61	Comparative Studies of the Enhancing Effects of Cyclodextrins on the Solubility and Oral Bioavailability of Tacrolimus in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 690-701.	1.6	113
62	Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. <i>Clinical Biochemistry</i> , 2001, 34, 285-290.	0.8	114
63	Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. <i>Bone Marrow Transplantation</i> , 2001, 28, 753-758.	1.3	59
64	Maintenance immunosuppression in the renal transplant recipient: An overview. <i>American Journal of Kidney Diseases</i> , 2001, 38, S25-S35.	2.1	96
65	Interspecies Scaling: Is a priori Knowledge of Cytochrome P450 Isozymes Involved in Drug Metabolism Helpful in Prediction of Clearance in Humans from Animal Data?. <i>Drug Metabolism and Drug Interactions</i> , 2001, 18, 135-47.	0.3	8
66	Immunosuppressive Drugs and Novel Strategies to Prevent Acute and Chronic Allograft Rejection. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2001, 22, 559-580.	0.8	11
67	Prediction of Clearance in Humans from In Vitro Human Liver Microsomes and Allometric Scaling. A Comparative Study of the Two Approaches. <i>Drug Metabolism and Drug Interactions</i> , 2002, 19, 49-64.	0.3	26
68	Identification of a Novel Route of Extraction of Sirolimus in Human Small Intestine: Roles of Metabolism and Secretion. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 174-186.	1.3	50
69	Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3091-3093.	1.4	145
70	C <sub>2</sub> (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1487-1490.	0.4	56
71	Comparison of an ELISA and an LC/MS/MS Method for Measuring Tacrolimus Concentrations and Making Dosage Decisions in Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 607-615.	1.0	45
72	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 451-457.	5.7	186

#	ARTICLE	IF	CITATIONS
73	Interspecies Scaling: Predicting Oral Clearance in Humans. <i>American Journal of Therapeutics</i> , 2002, 9, 35-42.	0.5	41
74	Roles of the Jejunum and Ileum in the First-Pass Effect as Absorptive Barriers for Orally Administered Tacrolimus. <i>Journal of Surgical Research</i> , 2002, 103, 215-222.	0.8	41
75	Drug Interactions with Tacrolimus. <i>Drug Safety</i> , 2002, 25, 707-712.	1.4	112
76	Immunosuppressive Therapy for Paediatric Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2002, 41, 115-135.	1.6	74
77	Pharmacokinetic Interaction Between Tacrolimus and Diltiazem. <i>Clinical Pharmacokinetics</i> , 2002, 41, 381-388.	1.6	61
78	Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus. <i>Clinical Pharmacokinetics</i> , 2002, 41, 813-851.	1.6	272
79	Sublingual Tacrolimus for Immunosuppression in Lung Transplantation. <i>Treatments in Respiratory Medicine</i> , 2002, 1, 91-98.	1.4	43
80	Oral FK 506 blood levels are elevated in pig short bowel model: further investigations with co-administration of an intestinal CYP3A4 inhibitor. <i>Transplantation Proceedings</i> , 2002, 34, 1050-1051.	0.3	8
81	Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. <i>Transplantation Proceedings</i> , 2002, 34, 1721-1722.	0.3	4
82	Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 1726-1729.	0.3	5
83	Are reduced tacrolimus dosages needed in the early postoperative period following living donor liver transplantation in adults?. <i>Transplantation Proceedings</i> , 2002, 34, 1531-1532.	0.3	7
84	Influence of hepatic ischemia-reperfusion injury on tacrolimus acute renal toxicity in pigs. <i>Transplantation Proceedings</i> , 2002, 34, 3053-3056.	0.3	1
85	Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. <i>Clinical Therapeutics</i> , 2002, 24, 330-350.	1.1	264
86	Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 719-729.	1.6	120
87	Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 597-605.	0.8	13
88	The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. <i>Liver Transplantation</i> , 2002, 8, 841-845.	1.3	95
89	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 245-254.	2.3	580
90	Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 130-137.	1.3	69

#	ARTICLE	IF	CITATIONS
91	Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. <i>Liver Transplantation</i> , 2003, 9, 954-960.	1.3	72
92	Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms. <i>American Journal of Transplantation</i> , 2003, 3, 477-483.	2.6	239
93	Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. <i>Analytica Chimica Acta</i> , 2003, 492, 133-145.	2.6	33
94	Two- to three-fold increase in blood tacrolimus (FK506) levels during diarrhea in liver-transplanted children. <i>Clinical Transplantation</i> , 2003, 17, 249-253.	0.8	18
95	Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. <i>Pediatric Transplantation</i> , 2003, 7, 474-478.	0.5	32
96	Factors affecting variability in distribution of tacrolimus in liver transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 298-309.	1.1	95
97	Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1161-1178.	1.6	38
98	Tacrolimus. <i>Drugs</i> , 2003, 63, 1247-1297.	4.9	373
99	Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. <i>Transplantation Proceedings</i> , 2003, 35, 1319-1321.	0.3	12
100	Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. <i>Transplantation Proceedings</i> , 2003, 35, 1314-1318.	0.3	22
101	Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation – acute rejection and complications. <i>Transplantation Proceedings</i> , 2003, 35, 1694-1696.	0.3	9
103	Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2409-2414.	0.4	149
104	The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 310-316.	1.3	56
105	Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. <i>American Journal of Veterinary Research</i> , 2003, 64, 926-934.	0.3	6
106	Bayesian Forecasting and Prediction of Tacrolimus Concentrations in Pediatric Liver and Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 158-166.	1.0	19
107	Coadministration of tacrolimus with anti-acid drugs. <i>Transplantation</i> , 2003, 76, 665-666.	0.5	6
108	Decreased Cyclosporin A Concentrations in the Absorption Phase Using Microemulsion Preconcentrate Formulation in Rats with Cisplatin-Induced Acute Renal Failure. <i>Biological and Pharmaceutical Bulletin</i> , 2003, 26, 1591-1595.	0.6	7
109	Ciclosporina A e tacrolimus: uma revisão. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2004, 40, 393-401.	0.3	11

#	ARTICLE	IF	CITATIONS
110	Therapeutic monitoring of immunosuppressant drugs. Where are we?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1204-11.	1.4	35
111	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2004, 110, 3858-3865.	1.6	200
112	Lansoprazoleâ€™ Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. <i>Annals of Pharmacotherapy</i> , 2004, 38, 791-794.	0.9	36
113	Monitoring of Immunosuppressive Therapy in Renal Transplanted Patients. , 2004, 146, 73-86.		3
114	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1895-1901.	0.4	83
115	Effect of Experimental Acute Renal and Hepatic Failure on Absorption of Tacrolimus in Rat Small Intestine. <i>Drug Metabolism and Pharmacokinetics</i> , 2004, 19, 190-197.	1.1	4
116	Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. <i>Clinical Transplantation</i> , 2004, 18, 585-590.	0.8	39
117	Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. <i>Transplant International</i> , 2004, 17, 643-646.	0.8	1
118	Pharmacokinetics of Sirolimus and Tacrolimus in Pediatric Transplant Patients. <i>American Journal of Transplantation</i> , 2004, 4, 767-773.	2.6	69
119	Tacrolimus Toxicity Associated with Concomitant Metoclopramide Therapy. <i>Pharmacotherapy</i> , 2004, 24, 532-537.	1.2	23
120	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1421-1425.	1.7	28
121	Liquid chromatographyâ€™negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 805, 13-20.	1.2	33
122	Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 352-361.	2.3	33
123	Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2004, 43, 623-653.	1.6	708
124	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. <i>Clinical Pharmacokinetics</i> , 2004, 43, 741-762.	1.6	102
125	Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. <i>Clinical Therapeutics</i> , 2004, 26, 1834-1844.	1.1	12
126	The colon displays an absorptive capacity of tacrolimus. <i>Transplantation Proceedings</i> , 2004, 36, 364-366.	0.3	7
127	Pharmacology of calcineurin antagonists. <i>Transplantation Proceedings</i> , 2004, 36, S25-S32.	0.3	126



#	ARTICLE	IF	CITATIONS
128	Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. <i>Transplantation Proceedings</i> , 2004, 36, 1506-1511.	0.3	34
129	Conversion from tacrolimus to cyclosporine for a non-dose-dependent tacrolimus-induced toxicity, a pediatric kidney transplant recipient case report. <i>Transplantation Proceedings</i> , 2004, 36, 1332-1335.	0.3	5
130	TACROLIMUS AND TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, S41-S43.	0.5	88
131	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 471-478.	5.7	182
132	Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 135-140.	1.0	130
133	Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 600-608.	1.0	65
134	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 147-154.	5.7	409
135	Sampling Times for Monitoring Tacrolimus in Stable Adult Liver Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 593-599.	1.0	21
136	Increased Bioavailability of Tacrolimus after Rectal Administration in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2004, 27, 1480-1482.	0.6	16
137	Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids. <i>Transplantation</i> , 2005, 80, 977-984.	0.5	104
138	Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1368-1372.	1.0	33
139	Hematocrit Influences Immunoassay Performance for the Measurement of Tacrolimus in Whole Blood. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 766-769.	1.0	33
140	Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 422-430.	1.0	51
141	Concomitant Clotrimazole Therapy More Than Doubles the Relative Oral Bioavailability of Tacrolimus. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 587-591.	1.0	22
142	Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. <i>Clinical Biochemistry</i> , 2005, 38, 552-557.	0.8	32
143	Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. <i>Clinical Transplantation</i> , 2005, 19, 638-643.	0.8	106
144	Altered metabolism of tacrolimus in hepatic veno-occlusive disease. <i>Transplant International</i> , 2005, 18, 1215-1217.	0.8	10
145	Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. <i>Biochemical Pharmacology</i> , 2005, 69, 561-568.	2.0	27

#	ARTICLE	IF	CITATIONS
146	Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 409-416.	0.8	54
147	Drug Therapy in the Heart Transplant Recipient. <i>Circulation</i> , 2005, 111, 230-239.	1.6	87
148	Potential Elevation of Tacrolimus Trough Concentrations with Concomitant Metronidazole Therapy. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1109-1113.	0.9	38
149	Intraindividual and Interindividual Variations in the Pharmacokinetics of Mycophenolic Acid in Liver Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 34-41.	1.0	69
150	PHARMACOKINETICS OF TACROLIMUS AND MYCOPHENOLIC ACID ARE ALTERED, BUT RECOVER AT DIFFERENT TIMES DURING HEPATIC REGENERATION IN RATS. <i>Drug Metabolism and Disposition</i> , 2005, 33, 329-335.	1.7	13
151	Cytochrome P450 3A polymorphisms and immunosuppressive drugs. <i>Pharmacogenomics</i> , 2005, 6, 37-47.	0.6	53
152	Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus. , 2005, , 321-359.		8
153	Psychomotor performance in lung transplant recipients: Simple reaction time. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 282-288.	0.3	1
154	Impact of CYP3A5 and MDR1(ABCB1) C3435T Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2005, 37, 1730-1732.	0.3	99
155	Pharmacokinetic Considerations Relating to Tacrolimus Dosing in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 541-557.	1.3	56
156	Population Pharmacokinetics of Tacrolimus in Whole Blood and Plasma in Asian Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2006, 45, 59-75.	1.6	59
157	Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients. <i>Current Therapeutic Research</i> , 2006, 67, 103-117.	0.5	3
158	Influence of CYP3A5 Gene Polymorphisms of Donor Rather than Recipient to Tacrolimus Individual Dose Requirement in Liver Transplantation. <i>Transplantation</i> , 2006, 81, 46-51.	0.5	65
159	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 119-127.	0.7	125
160	Pharmacogenetics in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 23-30.	1.0	34
161	Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation. <i>Pediatric Transplantation</i> , 2006, 10, 938-942.	0.5	23
162	Sirolimus pharmacokinetic differences between children and adults. <i>Pediatric Transplantation</i> , 2006, 10, 872-874.	0.5	3
163	Pharmacogenomics and lung transplantation: clinical implications. <i>Pharmacogenomics Journal</i> , 2006, 6, 301-310.	0.9	13

#	ARTICLE	IF	CITATIONS
164	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 90-102.	2.3	50
165	The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2006, 21, 719-724.	0.9	44
166	CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study. <i>American Journal of Transplantation</i> , 2006, 6, 2706-2713.	2.6	160
167	Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 28, 34-42.	1.9	37
168	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
169	Factors Affecting the Apparent Clearance of Tacrolimus in Korean Adult Liver Transplant Recipients. <i>Pharmacotherapy</i> , 2006, 26, 1069-1077.	1.2	34
170	The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 1192-8.	1.4	47
171	Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. <i>Pharmacogenomics</i> , 2006, 7, 563-574.	0.6	39
172	Role of P-glycoprotein in the hepatic metabolism of tacrolimus. <i>Xenobiotica</i> , 2006, 36, 1-13.	0.5	32
173	Transplant Pharmacy: 30 Years of Improving Patient Care. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1261-1263.	0.9	16
174	Tacrolimus in cardiac transplantation. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 131-138.	1.3	1
175	Metabolism of Tacrolimus (FK506) and Recent Topics in Clinical Pharmacokinetics. <i>Drug Metabolism and Pharmacokinetics</i> , 2007, 22, 328-335.	1.1	203
176	Tacrolimus Treatment in Myasthenia Gravis. <i>Current Drug Therapy</i> , 2007, 2, 53-56.	0.2	3
177	Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 305-314.	1.0	59
178	Analysis of Factors Influencing Tacrolimus Levels and Immunoassay Bias in Renal Transplantation. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 1035-1042.	1.0	8
179	Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 070621084156051-???	1.1	91
180	Effect of Cyclosporine and Tacrolimus on Cytochrome P450 Activities in Human Liver Microsomes. <i>Yakugaku Zasshi</i> , 2007, 127, 209-216.	0.0	45
181	Validation of a Liquid Chromatography-Mass Spectrometric Assay for Tacrolimus in Liver Biopsies After Hepatic Transplantation: Correlation With Histopathologic Staging of Rejection. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 340-348.	1.0	56

#	ARTICLE	IF	CITATIONS
182	Tacrolimus in Diabetic Kidney Transplant Recipients: Pharmacokinetics and Application of a Limited Sampling Strategy. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 391-398.	1.0	24
183	1199G&gt;A and 2677G&gt;T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 873-883.	0.7	94
184	Oral Tacrolimus Bioavailability Is Increased After Right Split Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 3237-3238.	0.3	1
185	Preliminary Evaluation of the New TACR Flex Method Versus MEIA Method in the Therapeutic Monitoring of Tacrolimus in Organ Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 2008-2009.	0.3	10
186	Transporter-mediated uptake into cellular compartments. <i>Xenobiotica</i> , 2007, 37, 1171-1195.	0.5	38
187	Performance of a no-pretreatment tacrolimus assay on the Dade Behring Dimension RxL clinical chemistry analyzer. <i>Clinica Chimica Acta</i> , 2007, 384, 48-51.	0.5	18
188	Diagnostic Tools for Monitoring Kidney Transplant Recipients. <i>Seminars in Nephrology</i> , 2007, 27, 462-478.	0.6	8
189	Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study. <i>Clinical Pharmacokinetics</i> , 2007, 46, 941-952.	1.6	56
190	Cytochrome P450 <i>CYP3A</i> polymorphisms and immunosuppressive drugs: an update. <i>Pharmacogenomics</i> , 2007, 8, 835-849.	0.6	91
191	CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 228-234.	2.3	118
192	CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 711-725.	2.3	192
193	Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. <i>Clinical Transplantation</i> , 2007, 21, 518-522.	0.8	4
194	Ethnopharmacology of Medicinal Plants: Asia and the Pacific. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 248-248.	1.1	49
195	Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 469-475.	1.1	89
196	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 ( <i>ABCB1</i> ) and cytochrome ( <i>CYP</i> ) 3A polymorphisms. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 427-435.	1.0	78
197	Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus. <i>Pharmacotherapy</i> , 2007, 27, 825-834.	1.2	119
198	Effect of Stabilizer on the Maximum Degree and Extent of Supersaturation and Oral Absorption of Tacrolimus Made By Ultra-Rapid Freezing. <i>Pharmaceutical Research</i> , 2008, 25, 167-175.	1.7	95
199	Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 93-94.	0.8	5

#	ARTICLE	IF	CITATIONS
200	Sublingual administration of tacrolimus in a renal transplant patient. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2008, 33, 87-89.	0.7	20
201	Tacrolimus in Renal Transplantation. , 2008, , 259-276.		15
202	Nebulization of nanoparticulate amorphous or crystalline tacrolimus â€“ Single-dose pharmacokinetics study in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 1057-1066.	2.0	46
203	Individualizing Therapy in Patients With Chronic Kidney Disease. <i>Journal of Pharmacy Practice</i> , 2008, 21, 225-236.	0.5	0
204	Binding of Pimecrolimus and Tacrolimus to Skin and Plasma Proteins: Implications for Systemic Exposure after Topical Application. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1812-1818.	1.7	41
205	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 610-616.	1.3	16
206	Absorption, Distribution, and Excretion of 14C-labeled Tacrolimus (FK506) after a Single or Repeated Ocular Instillation in Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2008, 24, 333-343.	0.6	12
207	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 313-317.	1.1	15
208	Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 469-475.	1.1	11
209	Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 226-228.	0.5	7
210	Pharmacodynamic Monitoring of Calcineurin Phosphatase Activity in Transplant Patients Treated with Calcineurin Inhibitors. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 150-157.	1.1	36
211	Effect of Tacrolimus on Activity and Expression of P-Glycoprotein and ATP-Binding Cassette Transporter A5 (ABCA5) Proteins in Hematoencephalic Barrier Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1911-1916.	0.6	15
212	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 413-423.	0.7	91
214	Limited Sampling Strategy for Simultaneous Estimation of the Area Under the Concentration-Time Curve of Tacrolimus and Mycophenolic Acid in Adult Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 52-59.	1.0	46
215	Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 861-868.	0.7	72
216	Haplotypic Structure of ABCB1/MDR1 Gene Modifies the Risk of the Acute Allograft Rejection in Renal Transplant Recipients. <i>Transplantation</i> , 2008, 86, 1206-1213.	0.5	59
217	Maturation of Dose-Corrected Tacrolimus Predose Trough Levels in Pediatric Kidney Allograft Recipients. <i>Transplantation</i> , 2008, 85, 1139-1145.	0.5	38
218	Pharmacokinetics of Tacrolimus in Living Donor Liver Transplant and Deceased Donor Liver Transplant Recipients. <i>Transplantation</i> , 2008, 85, 554-560.	0.5	14

#	ARTICLE	IF	CITATIONS
219	Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. <i>Drug Metabolism and Disposition</i> , 2009, 37, 821-826.	1.7	38
220	Species-dependent hepatic metabolism of immunosuppressive agent tacrolimus (FK-506). <i>Xenobiotica</i> , 2009, 39, 757-765.	0.5	3
221	Application of Fixed Exponent 0.75 to the Prediction of Human Drug Clearance: An Inaccurate and Misleading Concept. <i>Drug Metabolism and Drug Interactions</i> , 2009, 24, 57-82.	0.3	37
222	Role of Fixed Coefficients and Exponents in the Prediction of Human Drug Clearance: How Accurate are the Predictions from One or Two Species?. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2472-2493.	1.6	23
223	Study of the effect of Wuzhi tablet ( <i>Schisandra sphenanthera</i> extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. <i>Biomedical Chromatography</i> , 2010, 24, 399-405.	0.8	38
224	Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 380, 169-177.	1.4	46
225	CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 473-481.	0.8	43
226	Interindividual Variation of Maximal Blood Levels of Tacrolimus After Its Oral Administration in Hematopoietic Cell Transplant Recipients. <i>Transplantation Proceedings</i> , 2009, 41, 1831-1833.	0.3	4
227	Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus. <i>Transplantation Proceedings</i> , 2009, 41, 1557-1561.	0.3	44
228	Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 805-816.	1.6	117
229	Structural alterations in the seminiferous tubules of rats treated with immunosuppressor tacrolimus. <i>Reproductive Biology and Endocrinology</i> , 2009, 7, 19.	1.4	35
230	Tacrolimus in hematopoietic stem cell transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 835-841.	1.5	14
231	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	1.0	398
232	Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 187-197.	1.0	119
233	Time of Drug Administration, CYP3A5 and ABCB1 Genotypes, and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 734-742.	1.0	29
234	Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 436-442.	1.0	67
235	PREDICTIVE PERFORMANCES OF DIFFERENT THERAPEUTIC DRUG MONITORING APPROACHES TO ASSESS TACROLIMUS AND MYCOPHENOLIC ACID EXPOSURE. <i>Acta Clinica Belgica</i> , 2010, 65, 31-37.	0.5	0
236	Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 688-699.	1.0	32

#	ARTICLE	IF	CITATIONS
238	Pharmacokinetics and Bioavailability of Tacrolimus in Rats with Experimental Renal Dysfunction. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 1467-1472.	1.2	31
239	Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 65-70.	1.2	39
240	Explaining variability in ciclosporin exposure in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 579-590.	0.8	29
241	A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients. <i>Clinical Therapeutics</i> , 2010, 32, 2012-2023.	1.1	40
242	Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 516-532.	1.1	32
243	Mechanistic understanding of the different effects of Wuzhi Tablet ( <i>Schisandra sphenanthera</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 10. <i>International Journal of Pharmaceutics</i> , 2010, 389, 114-121.	2.6	89
244	An Integrative Approach for Identifying a Metabolic Phenotype Predictive of Individualized Pharmacokinetics of Tacrolimus. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 426-436.	2.3	73
245	The Application of Metabonomics to Predict Drug-Induced Liver Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 394-399.	2.3	67
246	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 886-891.	1.4	25
247	Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant Recipients. <i>Pharmaceutics</i> , 2010, 2, 291-299.	2.0	28
248	Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 107.	0.8	12
249	The effect of deoxyschisandrin on blood tacrolimus levels: a case report. <i>Immunopharmacology and Immunotoxicology</i> , 2010, 32, 177-178.	1.1	2
250	Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation. <i>Clinical Pharmacokinetics</i> , 2010, 49, 683-692.	1.6	81
251	Influence of CYP3A5 and MDR1(ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Chinese Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2010, 42, 3455-3458.	0.3	27
252	Sublingual Tacrolimus as an Alternative to Intravenous Route in Patients With Thoracic Transplant: A Retrospective Study. <i>Transplantation Proceedings</i> , 2010, 42, 4331-4337.	0.3	26
253	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 731-743.	1.5	34
254	Tacrolimus in the Treatment of Ocular Diseases. <i>BioDrugs</i> , 2011, 25, 89-103.	2.2	58
255	Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems. <i>Drug Development and Industrial Pharmacy</i> , 2011, 37, 1225-1230.	0.9	60

#	ARTICLE	IF	CITATIONS
256	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus,) Tj ETQq0 0 0 rgBT /Overloçk 10 Tf 50		
257	Management and Clinical Outcome of Penetrating Keratoplasty for Long-Term Corneal Changes in Sympathetic Ophthalmia. Journal of Ophthalmology, 2011, 2011, 1-5.	0.6	4
258	The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clinical Transplantation, 2011, 25, 146-150.	0.8	48
259	Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. Journal of Clinical Pharmacy and Therapeutics, 2011, 36, 614-624.	0.7	43
260	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. British Journal of Clinical Pharmacology, 2011, 71, 207-223.	1.1	43
261	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations " twice daily Prograf<sup>®</sup> and once daily Advagraf<sup>®</sup>. British Journal of Clinical Pharmacology, 2011, 71, 391-402.	1.1	93
262	Altered Bioavailability of Tacrolimus Following Intravenous Administration of Tigecycline. American Journal of Kidney Diseases, 2011, 57, 354.	2.1	12
263	Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. Acta Pharmacologica Sinica, 2011, 32, 1294-1302.	2.8	29
264	Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 25-33.	0.6	8
265	Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opinion on Drug Safety, 2011, 10, 9-22.	1.0	14
266	Impact of the <i>CYP3A4*1G</i> polymorphism and its combination with <i>CYP3A5</i> genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics, 2011, 12, 977-984.	0.6	69
267	Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients. Therapeutic Drug Monitoring, 2011, 33, 681-687.	1.0	23
268	The P450 oxidoreductase <i>*28</i> SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics, 2011, 12, 1281-1291.	0.6	116
269	Metabolomics in Toxicology: Preclinical and Clinical Applications. Toxicological Sciences, 2011, 120, S146-S170.	1.4	177
270	Pharmacogenetics of tacrolimus: ready for clinical translation?. Kidney International Supplements, 2011, 1, 58-62.	4.6	13
271	Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics Journal, 2011, 11, 300-306.	0.9	48
272	Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica, 2012, 42, 409-416.	0.5	50
273	Drug-Drug Interactions Between Antiretroviral and Immunosuppressive Agents in HIV-Infected Patients After Solid Organ Transplantation: A Review. AIDS Patient Care and STDs, 2012, 26, 568-581.	1.1	69



#	ARTICLE	IF	CITATIONS
274	Formulation strategies for drug delivery of tacrolimus: An overview. <i>International Journal of Pharmaceutical Investigation</i> , 2012, 2, 169.	0.2	58
275	Combinational Effect of Intestinal and Hepatic CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living Donor Liver Transplantation. <i>Transplantation</i> , 2012, 94, 866-872.	0.5	41
276	The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 32-42.	0.7	89
277	Food-drug Interaction of Tacrolimus with Pomelo, Ginger, and Turmeric Juice in Rats. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 242-247.	1.1	52
278	Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 463-472.	1.0	29
279	On-line solid-phase extraction high-performance liquid chromatography-tandem mass spectrometry for the quantitative analysis of tacrolimus in whole blood hemolyzate. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 863-874.	1.9	11
281	Tacrolimus trough levels before, during and after jejunostomy in a liver transplant patient: A case report. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, e126-e130.	0.7	3
282	Effect of CYP3A5, CYP3A4, and ABCB1 Genotypes as Determinants of Tacrolimus Dose and Clinical Outcomes After Heart Transplantation. <i>Transplantation Proceedings</i> , 2012, 44, 2635-2638.	0.3	26
283	Drug choices in autoimmune hepatitis: Part B – nonsteroids. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 617-635.	1.4	38
284	Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 657-669.	0.8	30
285	Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. <i>International Journal of Pharmaceutics</i> , 2012, 423, 341-350.	2.6	89
286	Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl- $\beta$ -cyclodextrin inclusion complex-loaded albumin nanoparticles. <i>International Journal of Pharmaceutics</i> , 2012, 427, 410-416.	2.6	62
287	Determination of four immunosuppressive drugs in whole blood using MEPS and LC-MS/MS allowing automated sample work-up and analysis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 897, 42-49.	1.2	56
288	Identification of Factors Affecting Tacrolimus Level and 5-Year Clinical Outcome in Kidney Transplant Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 217-223.	1.2	23
289	<i>Cryptosporidium</i> enteritis in solid organ transplant recipients: multicenter retrospective evaluation of 10 cases reveals an association with elevated tacrolimus concentrations. <i>Transplant Infectious Disease</i> , 2012, 14, 635-648.	0.7	50
290	Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. <i>Transplant International</i> , 2012, 25, 471-480.	0.8	75
291	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 259-266.	0.8	17
292	The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 835-842.	0.8	9

#	ARTICLE	IF	CITATIONS
293	Improvement of dissolution rate of tacrolimus by solid dispersion technique. <i>Journal of Pharmaceutical Investigation</i> , 2013, 43, 45-53.	2.7	7
294	Modigraf Administration Through Jejunostomy in Liver Transplant Recipient: Case Report. <i>Transplantation Proceedings</i> , 2013, 45, 3670-3671.	0.3	0
295	Effect of long-term co-administration of Wuzhi tablet ( <i>Schisandra sphenanthera</i> extract) and prednisone on the pharmacokinetics of tacrolimus. <i>Phytomedicine</i> , 2013, 20, 375-379.	2.3	37
296	Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy. <i>Cell</i> , 2013, 155, 1178-1187.	13.5	397
297	Effect of amlodipine on the pharmacokinetics of tacrolimus in rats. <i>Xenobiotica</i> , 2013, 43, 699-704.	0.5	10
298	Sublingual Tacrolimus: A Pharmacokinetic Evaluation Pilot Study. <i>Pharmacotherapy</i> , 2013, 33, 31-37.	1.2	22
299	The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: A meta-analysis. <i>Gene</i> , 2013, 531, 476-488.	1.0	12
300	From gut to kidney: Transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. <i>International Journal of Pharmaceutics</i> , 2013, 452, 14-35.	2.6	63
301	Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. <i>Xenobiotica</i> , 2013, 43, 641-649.	0.5	19
302	Metabolomics as a tool for personalizing medicine: 2012 update. <i>Personalized Medicine</i> , 2013, 10, 149-161.	0.8	22
303	Pharmacokinetics of a self-microemulsifying drug delivery system of tacrolimus. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 469-473.	2.5	10
304	Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 53-63.	0.8	62
305	Self micro-emulsifying drug delivery system of tacrolimus: Formulation, in vitro evaluation and stability studies. <i>International Journal of Pharmaceutical Investigation</i> , 2013, 3, 95.	0.2	48
306	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 563-585.	0.7	184
307	Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. <i>Saudi Journal of Gastroenterology</i> , 2013, 19, 89.	0.5	4
308	A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. <i>Clinical Transplantation</i> , 2013, 27, E685-93.	0.8	15
309	Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. <i>Renal Failure</i> , 2013, 35, 942-945.	0.8	9
310	Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism – a prospective, randomized, controlled study. <i>Clinical Transplantation</i> , 2013, 27, E272-81.	0.8	38

#	ARTICLE	IF	CITATIONS
311	Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as anti-prion agents. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7044-7049.	3.3	86
312	Influence of Cytochrome P450 (CYP) $3A4^{*1G}$ Polymorphism on the Pharmacokinetics of Tacrolimus, Probability of Acute Cellular Rejection, and mRNA Expression Level of CYP3A5 Rather than CYP3A4 in Living-Donor Liver Transplant Patients. Biological and Pharmaceutical Bulletin, 2013, 36, 1814-1821.	0.6	31
313	Pretransplantation Pharmacokinetic Assessments to Predict Posttransplantation Dosing Requirements in renal Transplant Recipients: What Is Known?. Clinical Pharmacology and Therapeutics, 2013, 93, 306-307.	2.3	2
314	Infliximab salvage therapy for patients with ulcerative colitis who failed to respond to tacrolimus. European Journal of Gastroenterology and Hepatology, 2013, 25, 714-718.	0.8	14
315	Pretransplantation Pharmacokinetic Curves of Tacrolimus in HIV-Infected Patients on Ritonavir-Containing cART. Transplantation, 2013, 95, 397-402.	0.5	31
316	Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World Journal of Gastroenterology, 2013, 19, 9156.	1.4	78
317	Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. , 2013, , .		1
318	Pharmacometabolomics: Current Applications and Future Perspectives. Translational and Clinical Pharmacology, 2014, 22, 8.	0.3	7
319	Intestinal P-glycoprotein Expression is Multimodally Regulated by Intestinal Ischemia-Reperfusion. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 266.	0.9	20
320	Calcineurin Inhibitors. , 2014, , 231-249.		7
321	Calcineurin inhibitors and hypertension: a role for pharmacogenetics?. Pharmacogenomics, 2014, 15, 1243-1251.	0.6	20
322	Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenetics and Genomics, 2014, 24, 356-366.	0.7	29
323	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 71-79.	1.0	81
324	Rapid Resolution of Tacrolimus Intoxicationâ€“Induced AKI With a Corticosteroid and Phenytoin. Annals of Pharmacotherapy, 2014, 48, 1525-1528.	0.9	12
325	Fundamentals of Bioequivalence. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 29-53.	0.2	3
326	The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. European Journal of Drug Metabolism and Pharmacokinetics, 2014, 39, 243-253.	0.6	12
327	Equilibrium Gel Filtration to Measure Plasma Protein Binding of Very Highly Bound Drugs. Journal of Pharmaceutical Sciences, 2014, 103, 752-759.	1.6	13
328	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. AAPS Journal, 2014, 16, 379-391.	2.2	37

#	ARTICLE	IF	CITATIONS
329	In Vivo to In Vitro Effects of Six Bioactive Lignans of Wuzhi Tablet (<i>Schisandra Sphenanthera</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Metabolism and Disposition, 2014, 42, 193-199.	1.7	51
330	Identification and Characterization of a Defective CYP3A4 Genotype in a Kidney Transplant Patient With Severely Diminished Tacrolimus Clearance. Clinical Pharmacology and Therapeutics, 2014, 95, 416-422.	2.3	36
331	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 2014, 53, 123-139.	1.6	186
332	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. British Journal of Clinical Pharmacology, 2014, 77, 1051-1063.	1.1	23
333	Rapid and Sensitive UPLCâ€“MS-MS Determination of Tacrolimus in Wistar Rats and Human Blood. Journal of Chromatographic Science, 2014, 52, 59-67.	0.7	13
334	The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European Journal of Clinical Pharmacology, 2014, 70, 685-693.	0.8	107
335	Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Canadian Journal of Physiology and Pharmacology, 2014, 92, 50-57.	0.7	7
336	Total plasma protein effect on tacrolimus elimination in kidney transplant patients â€“ Population pharmacokinetic approach. European Journal of Pharmaceutical Sciences, 2014, 52, 34-40.	1.9	28
337	The Serum Concentration of Tacrolimus After Ingesting Omeprazole. Transplantation, 2014, 98, e63-e64.	0.5	3
338	Systemic use of nonâ€“biologic agents in orofacial diseases: other immunomodulatory agents. Oral Diseases, 2015, 21, 273-282.	1.5	4
339	Intracellular sirolimus concentration is reduced by tacrolimus in human pancreatic islets inÂvitro. Transplant International, 2015, 28, 1152-1161.	0.8	7
340	Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. British Journal of Clinical Pharmacology, 2015, 80, 548-559.	1.1	48
341	Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time. Therapeutic Drug Monitoring, 2015, 37, 524-530.	1.0	4
342	Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation. British Journal of Clinical Pharmacology, 2015, 80, 630-641.	1.1	33
343	Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus. Therapeutic Drug Monitoring, 2015, 37, 288-295.	1.0	42
344	Systematic Review. Inflammatory Bowel Diseases, 2015, 21, 1683-1694.	0.9	64
345	Multifunctional Poly(methyl vinyl ether-<i>co</i>-maleic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 107 Td (anhydride)-<i>graft</i>-hydroxy High-Performance Delivery Carrier of Tacrolimus. Molecular Pharmaceutics, 2015, 12, 2337-2351.	2.3	48
346	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. European Journal of Clinical Pharmacology, 2015, 71, 773-799.	0.8	15

#	ARTICLE	IF	CITATIONS
347	A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 281-288.	2.8	40
348	Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. <i>Pediatric Nephrology</i> , 2015, 30, 1961-1967.	0.9	25
349	Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial. <i>Journal of Dermatological Treatment</i> , 2015, 26, 90-93.	1.1	12
350	Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 535-543.	2.8	20
351	Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 921-936.	1.5	28
352	The emerging role of tacrolimus in myasthenia gravis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 92-103.	1.5	60
353	Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2015, 54, 599-614.	1.6	4
354	Dose increase needed in most cystic fibrosis lung transplantation patients when changing from twice-to once-daily tacrolimus oral administration. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 715-722.	0.8	9
355	Effects of <i>CYP3A5</i> genotypes, <i>ABCB1</i> C3435T and <i>G2677T/A</i> polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. <i>Xenobiotica</i> , 2015, 45, 840-846.	0.5	37
356	Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 246-255.	1.0	29
357	Fujicalin®-based solid supersaturable self-emulsifying drug delivery system (S-SEDDS) of tacrolimus for enhanced dissolution rate and oral absorption. <i>Journal of Pharmaceutical Investigation</i> , 2015, 45, 651-658.	2.7	10
358	Orosomucoid binding induced amplification of inherent chirality of the immunosuppressant drug sirolimus. <i>RSC Advances</i> , 2015, 5, 84523-84525.	1.7	2
359	Interactive effects of <i>CYP3A4</i> , <i>CYP3A5</i> , <i>MDR1</i> and <i>NR1I2</i> polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. <i>Pharmacogenomics</i> , 2015, 16, 1355-1365.	0.6	39
360	Therapeutic Drug Monitoring of Tacrolimus in Saudi Kidney Transplant Patients. <i>Journal of Nephrology &amp; Therapeutics</i> , 2016, 06, .	0.1	2
361	Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system. <i>International Journal of Nanomedicine</i> , 2016, 11, 1109.	3.3	20
362	Pretransplant Tacrolimus Dose Requirements Predict Early Posttransplant Dose Requirements in Blood Group ABO-Incompatible Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 217-222.	1.0	3
363	Cryptosporidiosis Treated With Nitazoxanide in Intestinal Transplantation. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 177-179.	0.1	0
364	Sublingual administration improves systemic exposure of tacrolimus in kidney transplant recipients: comparison with oral administration. <i>European Journal of Clinical Investigation</i> , 2016, 46, 651-657.	1.7	7

#	ARTICLE	IF	CITATIONS
365	Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 310-328.	0.7	34
366	A high inpatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. <i>Transplant International</i> , 2016, 29, 1158-1167.	0.8	108
367	External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 891-907.	1.1	82
368	Preparation of extended release solid dispersion formulations of tacrolimus using ethylcellulose and hydroxypropylmethylcellulose by solvent evaporation method. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 316-323.	1.2	29
369	Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. <i>International Journal of Urology</i> , 2016, 23, 484-490.	0.5	5
370	New strategy of tacrolimus administration in animal model based on tacrolimus-loaded microspheres. <i>Transplant Immunology</i> , 2016, 36, 9-13.	0.6	7
371	Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2016, 48, 1087-1094.	0.3	11
372	Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 408-413.	1.0	39
373	Experiences from using LC-MS/MS for analysis of immunosuppressive drugs in a TDM service. <i>Clinical Biochemistry</i> , 2016, 49, 1024-1031.	0.8	15
374	A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. <i>Journal of Chromatography A</i> , 2016, 1475, 55-63.	1.8	17
375	Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016, 134, e468-e495.	1.6	203
376	In vitro and in silico characterisation of Tacrolimus released under biorelevant conditions. <i>International Journal of Pharmaceutics</i> , 2016, 515, 271-280.	2.6	16
377	Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant. <i>Transplantation</i> , 2016, 100, 2099-2106.	0.5	29
378	Advagraf <sup>®</sup> , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. <i>Transplant International</i> , 2016, 29, 860-869.	0.8	34
379	Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes. <i>AAPS PharmSciTech</i> , 2016, 17, 1019-1029.	1.5	20
380	Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. <i>International Journal of Biological Macromolecules</i> , 2016, 83, 282-287.	3.6	27
381	Current methods of the analysis of immunosuppressive agents in clinical materials: A review. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 127, 207-231.	1.4	66
382	Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience. <i>Biomarkers</i> , 2016, 21, 335-341.	0.9	7

#	ARTICLE	IF	CITATIONS
383	Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. <i>Drug Metabolism Reviews</i> , 2016, 48, 88-112.	1.5	119
384	A rapid and sensitive method to determine tacrolimus in rat whole blood using liquid-liquid extraction with mild temperature ultrasonication and LC-MS/MS. <i>Archives of Pharmacal Research</i> , 2016, 39, 73-82.	2.7	9
385	Intracellular concentrations of immunosuppressants. , 2016, , 199-226.		10
386	Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. <i>Journal of Nephrology</i> , 2016, 29, 269-276.	0.9	54
387	Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. <i>Pharmacogenomics Journal</i> , 2017, 17, 61-68.	0.9	60
388	IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 415-423.	2.8	26
389	Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. <i>Transplant Infectious Disease</i> , 2017, 19, e12662.	0.7	6
390	The CYP3A biomarker 4 $\beta$ -hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1457-1465.	1.1	19
391	Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 787-796.	0.7	6
392	A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon $\alpha$ -2a in Hepatitis C Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1369-1379.	1.6	5
393	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1491-1498.	1.6	39
394	Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 198-200.	0.3	24
395	Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 361-368.	0.7	11
396	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. <i>Clinical Pharmacokinetics</i> , 2017, 56, 963-975.	1.6	69
397	Effect of ABCB1 (3435C>T) and CYP3A5 (6986A>G) genes polymorphism on tacrolimus concentrations and dosage requirements in liver transplant patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2017, 18, 261-268.	0.5	9
398	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 679-688.	0.7	22
399	Using known drug interactions to manage suprathreshold calcineurin inhibitor concentrations. <i>Clinical Transplantation</i> , 2017, 31, e13098.	0.8	7
400	Single synchronous delivery of FK506-loaded polymeric microspheres with pancreatic islets for the successful treatment of streptozocin-induced diabetes in mice. <i>Drug Delivery</i> , 2017, 24, 1350-1359.	2.5	29

#	ARTICLE	IF	CITATIONS
401	Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1602449.	3.1	119
402	Wuzhi Tablet (<i>Schisandra sphenanthera</i> Extract) Is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who Are CYP3A5 Expressers: a Two-Phase Prospective Study. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1114-1119.	1.7	31
403	Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 3114-3122.	2.6	56
404	Association Between Tacrolimus Pharmacokinetics and Cytochrome P450 3A5 and Multidrug Resistance Protein 1 Exon 21 Polymorphisms. <i>Transplantation Proceedings</i> , 2017, 49, 1492-1498.	0.3	5
405	Overview of Immunosuppressive Therapy in Solid Organ Transplantation. <i>Anesthesiology Clinics</i> , 2017, 35, 365-380.	0.6	73
406	Impact of inpatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol. <i>BMJ Open</i> , 2017, 7, e016144.	0.8	4
407	Evaluation of the Crystallization Tendency of Commercially Available Amorphous Tacrolimus Formulations Exposed to Different Stress Conditions. <i>Pharmaceutical Research</i> , 2017, 34, 2142-2155.	1.7	29
408	<i>Clostridium difficile</i> -Associated Colitis Post-Transplant Is Not Associated with Elevation of Tacrolimus Concentrations. <i>Surgical Infections</i> , 2017, 18, 689-693.	0.7	1
409	Non-Sink Dissolution Behavior and Solubility Limit of Commercial Tacrolimus Amorphous Formulations. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 264-272.	1.6	27
410	Development and characterization of methoxy poly(ethylene oxide)- block -poly( $\mu$ -caprolactone) (PEO- b) Tj ETQq1 1 0.784314 rgBT Journal, 2017, 25, 258-265.	1.2	17
411	Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice. <i>Xenobiotica</i> , 2017, 47, 752-762.	0.5	1
412	Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. <i>Cellular and Molecular Immunology</i> , 2017, 14, 146-179.	4.8	99
413	Influence of tacrolimus metabolism rate on renal function after solid organ transplantation. <i>World Journal of Transplantation</i> , 2017, 7, 26.	0.6	21
414	Effectiveness of Measuring Genetic Polymorphisms in Metabolizing Enzymes of Tacrolimus within One Medical Facility. <i>Journal of Nippon Medical School</i> , 2017, 84, 274-279.	0.3	1
415	Individualizing Transplant Therapy. , 2017, , 255-279.		2
416	Pharmacokinetics and Genomics of Immunosuppressive Drugs. , 2017, , 429-443.		1
417	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1075-1106.	1.6	21
418	A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. <i>Journal of Chromatography A</i> , 2018, 1547, 45-52.	1.8	16



#	ARTICLE	IF	CITATIONS
419	Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 1527-1533.	2.6	37
420	Bariatric surgery in solid organ transplant patients: Long-term follow-up results of outcome, safety, and effect on immunosuppression. <i>American Journal of Transplantation</i> , 2018, 18, 2772-2780.	2.6	47
421	<i>CYP3A5</i> and <i>ABCB1</i> Significantly Influence Dose-Adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 320-326.	1.2	27
422	Phenytoin and Rifampin Do Not Decrease Levels in Acute Tacrolimus Toxicity. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961876586.	0.3	1
423	Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1330-1341.	1.6	53
424	Formulation and in vivo pharmacokinetic evaluation of ethyl cellulose-coated sustained release multiple-unit system of tacrolimus. <i>International Journal of Biological Macromolecules</i> , 2018, 109, 544-550.	3.6	17
425	Dose-Response Relationship Between Diltiazem and Tacrolimus and Its Safety in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 2515-2520.	0.3	8
426	Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 292-300.	1.0	10
427	Weight of <i>ABCB1</i> and <i>POR</i> genes on oral tacrolimus exposure in <i>CYP3A5</i> nonexpressor pediatric patients with stable kidney transplant. <i>Pharmacogenomics Journal</i> , 2018, 18, 180-186.	0.9	12
428	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 475-489.	1.6	48
429	<i>CYP3A</i> genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 53-60.	0.8	7
430	Association of <i>CYP3A5</i> , <i>CYP2C8</i> , and <i>ABCB1</i> Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus. <i>Transplantation Proceedings</i> , 2018, 50, 3258-3265.	0.3	8
431	Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 476-483.	0.7	22
432	Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2527-2542.	0.9	28
433	Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. <i>Clinical Transplantation</i> , 2018, 32, e13332.	0.8	18
434	Review of Major Drug-Drug Interactions in Thoracic Transplantation. <i>Current Transplantation Reports</i> , 2018, 5, 220-230.	0.9	0
435	Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. <i>Current Drug Metabolism</i> , 2018, 19, 513-522.	0.7	103
436	Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different <i>CYP3A5</i> genotypes. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1437-1447.	0.8	13

#	ARTICLE	IF	CITATIONS
437	Large-Scale Variability of Inpatient Tacrolimus Therapeutic Drug Monitoring at an Academic Transplant Center: A Retrospective Study. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 394-400.	1.0	9
438	Effects of clotrimazole troches on tacrolimus dosing in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12979.	0.7	7
439	Application of quasi-emulsification and modified double emulsification techniques for formulation of tacrolimus microsponges. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 4537-4548.	3.3	12
440	Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 549-557.	1.0	16
441	Biomarkers for individualized dosage adjustments in immunosuppressive therapy using calcineurin inhibitors after organ transplantation. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 151-159.	2.8	22
442	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	1.6	91
444	Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3210.	1.8	25
445	Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf <sup>®</sup> or non-innovator formulations. <i>Pediatric Transplantation</i> , 2019, 23, e13595.	0.5	5
446	Impact of <i>CYP3A4/5</i> and <i>ABCB1</i> polymorphisms on tacrolimus exposure and response in pediatric primary nephrotic syndrome. <i>Pharmacogenomics</i> , 2019, 20, 1071-1083.	0.6	16
447	Graft-implanted, enzyme responsive, tacrolimus-eluting hydrogel enables long-term survival of orthotopic porcine limb vascularized composite allografts: A proof of concept study. <i>PLoS ONE</i> , 2019, 14, e0210914.	1.1	12
448	A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the <i>cytochrome P450 3A5 (CYP3A5)</i> Genotype. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 587-595.	1.3	7
449	Genome-Wide Association Study of Tacrolimus Pharmacokinetics Identifies Novel Single Nucleotide Polymorphisms in the Convalescence and Stabilization Periods of Post-transplant Liver Function. <i>Frontiers in Genetics</i> , 2019, 10, 528.	1.1	10
450	Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2413.	1.8	23
451	Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 4023-4031.	0.8	10
452	FK506 Induces Ligand-Independent Activation of the Bone Morphogenetic Protein Pathway and Osteogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1900.	1.8	16
453	Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 611-617.	0.7	26
454	Intra-patient variability in tacrolimus exposure in pediatric liver transplant recipients: Evolution, risk factors, and impact on patient outcomes. <i>Pediatric Transplantation</i> , 2019, 23, e13388.	0.5	16
455	Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 879-888.	0.8	5

#	ARTICLE	IF	CITATIONS
456	Reduction of exposure to tacrolimus trough level variability is associated with better graft survival after kidney transplantation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 951-958.	0.8	15
457	Natural product drug delivery: A special challenge?. <i>Progress in Medicinal Chemistry</i> , 2019, 58, 157-187.	4.1	13
458	Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype. <i>Transplantation Proceedings</i> , 2019, 51, 2917-2920.	0.3	7
459	Calcineurin Inhibitors. , 2019, , 242-260.		1
460	Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study. <i>Transplantation Direct</i> , 2019, 5, e485.	0.8	11
461	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	1.0	374
462	Extended tacrolimus release via the combination of lipid-based solid dispersion and HPMC hydrogel matrix tablets. <i>Asian Journal of Pharmaceutical Sciences</i> , 2019, 14, 445-454.	4.3	20
463	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	1.1	56
464	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 65-71.	1.1	1
465	Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites. <i>Drug Metabolism and Disposition</i> , 2019, 47, 194-202.	1.7	91
466	Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 55-63.	1.2	18
467	Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 656-663.	2.0	20
468	Clinical aspects of tacrolimus use in paediatric renal transplant recipients. <i>Pediatric Nephrology</i> , 2019, 34, 31-43.	0.9	20
469	Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. <i>Xenobiotica</i> , 2020, 50, 371-379.	0.5	22
470	Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. <i>Xenobiotica</i> , 2020, 50, 188-195.	0.5	19
471	Pharmacogenomics analysis in Chinese pediatric liver transplantation patients with renal toxicity induced by tacrolimus. <i>Xenobiotica</i> , 2020, 50, 488-493.	0.5	7
472	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. <i>Clinical Pharmacokinetics</i> , 2020, 59, 591-603.	1.6	14
473	Clickable, acid labile immunosuppressive prodrugs for <i>in vivo</i> targeting. <i>Biomaterials Science</i> , 2020, 8, 266-277.	2.6	16

#	ARTICLE	IF	CITATIONS
474	Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105199.	1.9	16
475	Evaluation of Concentration Errors and Inappropriate Dose Tailoring of Tacrolimus Caused by Sampling-Time Deviations in Pediatric Patients With Primary Nephrotic Syndrome. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 392-399.	1.0	3
476	Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the <i>CYP3A5</i> polymorphism and coadministration with Wuzhi capsule. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 309-317.	0.7	12
477	Initial tacrolimus weight-based dosing strategy in allogeneic hematopoietic stem-cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1447-1453.	0.5	6
478	Pharmacokinetics and Biodistribution of Tacrolimus after Topical Administration: Implications for Vascularized Composite Allotransplantation. <i>Pharmaceutical Research</i> , 2020, 37, 222.	1.7	3
479	Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. <i>Theranostics</i> , 2020, 10, 11278-11301.	4.6	56
480	Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , 2020, 13, 1327-1335.	1.5	9
481	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 769-782.	1.5	19
482	Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1357-1392.	1.6	29
483	Diagnosis and management of oral ulcerations associated with mycophenolate mofetil in kidney transplantation. <i>Special Care in Dentistry</i> , 2020, 40, 605-610.	0.4	3
484	Impact of the Post-Transplant Period and Lifestyle Diseases on Human Gut Microbiota in Kidney Graft Recipients. <i>Microorganisms</i> , 2020, 8, 1724.	1.6	16
486	Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 553-561.	1.3	14
487	Effects of red blood cell concentrate transfusion on blood tacrolimus concentration. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 956-964.	1.0	4
488	Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 453-466.	0.6	7
489	Novel methodology to perform incurred sample reanalysis on dried blood spot cards: Experimental data using darolutamide and filgotinib. <i>Biomedical Chromatography</i> , 2020, 34, e4938.	0.8	2
490	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 858.	1.8	16
491	Fabrication and Characterization of Thiolated Chitosan Microneedle Patch for Transdermal Delivery of Tacrolimus. <i>AAPS PharmSciTech</i> , 2020, 21, 68.	1.5	46
492	Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity. <i>Scientific Reports</i> , 2020, 10, 6675.	1.6	11

#	ARTICLE	IF	CITATIONS
493	Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. <i>International Journal of Medical Sciences</i> , 2020, 17, 859-864.	1.1	7
494	Body weight-based initial dosing of tacrolimus in renal transplantation: Is this an ideal approach?. <i>Journal of Renal Care</i> , 2021, 47, 51-57.	0.6	6
495	Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 857-862.	0.5	2
496	Multiple microRNAs regulate tacrolimus metabolism through CYP3A5. <i>Pharmacological Research</i> , 2021, 164, 105382.	3.1	5
497	Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. <i>Annals of Pharmacotherapy</i> , 2021, 55, 440-451.	0.9	7
498	Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 71-77.	0.8	7
499	Tacrolimus-Induced Bradykinesia Secondary to Phenoconversion in an Elderly Post-Bilateral Lung Transplant Patient. , 2021, 36, 34-41.		1
500	Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists. <i>Journal of Rheumatic Diseases</i> , 2021, 28, 4-16.	0.4	7
501	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021, 11, 443.	1.6	6
502	Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 401-407.	1.0	6
503	Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1035-1044.	1.0	3
504	Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 387-394.	0.5	0
505	Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2284-2292.	0.4	8
506	Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Pharmacokinetics</i> , 2021, 60, 877-885.	1.6	4
507	Relationship between CYP3A5 Polymorphism and Tacrolimus Blood Concentration Changes in Allogeneic Hematopoietic Stem Cell Transplant Recipients during Continuous Infusion. <i>Pharmaceutics</i> , 2021, 14, 353.	1.7	3
508	Self-microemulsification-assisted incorporation of tacrolimus into hydrophilic nanofibers for facilitated treatment of 2,4-dinitrochlorobenzene induced atopic dermatitis like lesions. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 62, 102326.	1.4	5
509	A Safety and Tolerability Study of Thin Film Freeze-Dried Tacrolimus for Local Pulmonary Drug Delivery in Human Subjects. <i>Pharmaceutics</i> , 2021, 13, 717.	2.0	6
510	Establishment of an experimental rat model of tacrolimus-induced kidney injury accompanied by interstitial fibrosis. <i>Toxicology Letters</i> , 2021, 341, 43-50.	0.4	4

#	ARTICLE	IF	CITATIONS
511	The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. <i>Pharmacological Reports</i> , 2021, 73, 1418-1426.	1.5	3
512	Tacrolimus Therapy in Adult Heart Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, Publish Ahead of Print, 736-746.	1.0	3
513	Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2281-2289.	1.0	7
514	Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 490-498.	1.0	5
515	Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	3
516	Influential Factors and Efficacy Analysis of Tacrolimus Concentration After Allogeneic Hematopoietic Stem Cell Transplantation in Children with $\beta^2$ -Thalassemia Major. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1221-1237.	0.4	1
517	Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 19.e1-19.e7.	0.6	6
518	New insights into the microbiome in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 582-586.	0.8	5
519	Overview of therapeutic drug monitoring of immunosuppressive drugs: Analytical and clinical practices. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114315.	1.4	13
520	Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 40, 100407.	1.1	3
521	Extrapolation of physiologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100423.	1.1	2
522	Post-transplant Medication Challenges. , 2021, , 305-356.		0
523	Immunosuppressive Drugs. , 2008, , 165-199.		4
524	Quantitation of Tacrolimus in Whole Blood Using High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS-MS). <i>Methods in Molecular Biology</i> , 2010, 603, 479-487.	0.4	4
525	Therapeutic Drugs and Their Management. , 2012, , 1057-1108.		3
526	Immunosuppressant drugs - the role of therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 61-73.	1.1	15
527	Immunosuppressive Agents in Clinical Trials in Transplantation. <i>American Journal of the Medical Sciences</i> , 1997, 313, 283-288.	0.4	29
528	Monitoring of Tacrolimus as Rescue Therapy in Pediatric Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 376-379.	1.0	16

#	ARTICLE	IF	CITATIONS
529	Therapeutic Drug Monitoring of Tacrolimus in Liver Transplantation, Phase III FK506 Multicenter Spanish Study Group: A Two-Year Follow-Up. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 602-606.	1.0	10
530	Multicenter Comparison of First- and Second-Generation IMx Tacrolimus Microparticle Enzyme Immunoassays in Liver and Kidney Transplantation. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 676-679.	1.0	10
531	Analysis of Whole Blood Tacrolimus Concentrations in Liver Transplant Patients Exhibiting Impaired Liver Function. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 585.	1.0	12
532	MECHANISM OF FIBROSIS IN EXPERIMENTAL TACROLIMUS NEPHROTOXICITY <sup>1,2</sup> . <i>Transplantation</i> , 1997, 64, 1829-1837.	0.5	99
533	RELATIONSHIP BETWEEN IN VIVO FK506 CLEARANCE AND IN VITRO 13-DEMETHYLATION ACTIVITY IN LIVING-RELATED LIVER TRANSPLANTATION. <i>Transplantation</i> , 1998, 66, 1089-1093.	0.5	12
534	SERIOUS INTERACTION BETWEEN MIBEFRADIL AND TACROLIMUS <sup>1</sup> . <i>Transplantation</i> , 1998, 66, 1113-1115.	0.5	24
535	POPULATION PHARMACOKINETICS OF TACROLIMUS IN CHILDREN WHO RECEIVE CUT-DOWN OR FULL LIVER TRANSPLANTS. <i>Transplantation</i> , 2001, 72, 1056-1061.	0.5	38
536	Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 713-720.	0.7	64
537	Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 364-370.	1.0	14
538	Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 358-363.	1.0	13
539	Thirty Years of Tacrolimus in Clinical Practice. <i>Transplantation</i> , 2021, 105, 484-495.	0.5	31
540	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. <i>Annals of Transplantation</i> , 2020, 25, e923278.	0.5	6
541	Renal Allograft Dysfunction Associated with Rifampin-Tacrolimus Interaction. , 0, .		1
542	Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation. <i>PLoS ONE</i> , 2015, 10, e0122399.	1.1	133
543	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, S1-S86.	3.0	514
545	Conversion ratio of tacrolimus switching from intravenous infusion to oral administration after lung transplantation. <i>Journal of Thoracic Disease</i> , 2020, 12, 4292-4298.	0.6	3
546	Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: The influence of gender and comedication. <i>Vojnosanitetski Pregled</i> , 2015, 72, 813-822.	0.1	16
547	Tacrolimus dosage requirements in living donor liver transplant recipients with small-for-size grafts. <i>World Journal of Gastroenterology</i> , 2009, 15, 3931.	1.4	8

#	ARTICLE	IF	CITATIONS
548	Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2181-2188.	1.8	10
549	Determination of Tacrolimus in Rat Whole Blood Utilizing Triple Quadrupole LC/MS. <i>Journal of Analytical &amp; Bioanalytical Techniques</i> , 2011, 02, .	0.6	7
550	Influences of Donor and Recipient Gene Polymorphisms on Tacrolimus Dosing and Pharmacokinetics in Asian Liver Transplant Patients. <i>Open Journal of Organ Transplant Surgery</i> , 2013, 03, 53-61.	0.3	5
551	Clinical Pharmacokinetics of Oral Versus Sublingual Administration of Tacrolimus in Adult Liver Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , 2012, 10, 586-591.	0.2	21
552	Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences. <i>Experimental and Clinical Transplantation</i> , 2017, 15, 1-9.	0.2	29
553	Tacrolimus for Ophthalmic Use: An Update. <i>Delhi Journal of Ophthalmology</i> , 2013, 23, 211-215.	0.0	5
554	Tacrolimus Dose-Conversion Ratios Based on Switching of Formulations for Patients with Solid Organ Transplants. <i>Canadian Journal of Hospital Pharmacy</i> , 2021, 74, 317-326.	0.1	0
555	CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation. <i>Gene</i> , 2022, 809, 146007.	1.0	12
556	Distribution evaluation of tacrolimus in the ascitic fluid of liver transplant recipients with liver cirrhosis by a sensitive ultra-performance LC-MS/MS method. <i>Journal of Separation Science</i> , 2021, , .	1.3	0
557	Title is missing!. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.	0.1	0
558	The potential role of immunosuppressive macrocyclic lactones. , 2001, , 43-75.		0
560	ç”Yä1/2“è,çS»ææ,£è€...ã«ãšã‘ã,ã°è...P-ç³—è>ç™1/2èè³ãç™ç³/4â%ã•ã“ã,ã,ãfãfãfã,1è¡ã,æ¿fã°   æŽ”çS»ã“ã©ççé-ç. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.		0
561	ç”Yä1/2“è,çS»ææ,£è€...ã«ãšã‘ã,ã°è...P-ç³—è>ç™1/2èè³ãç™ç³/4â%ã•ã“ã,ã,ãfãfãfã,1ä1/2“ât...ã•æ...ã“ã©æ”è1çfèS£æž. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.		0
562	ã°è...çS»æç—†ã³/4ã«ãšã‘ã,ã°è...MDR1ç™ç³/4â%ã•ã“ã,ã,ãfãfãfã,1æš•ãŽçµCEè-ã°éæšž. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.		0
563	ç”Yä1/2“è,çS»ææ,£è€...ã«ãšã‘ã,ãf™ã,ã,ã,çãf³æ³•ã,ç”ã,ãŸã,ã,ãfãfãfã,1è†³é©æš•ãŽè”~. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.		0
564	6.ç”Yä1/2“è,çS»æãã,ã°ã³ãã°è...çS»æè¡“ã³/4CEã°ã,ã,ãfãfãfã,1æš•ãŽæ—1æ³•. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2001, 32, 267S-268S.		0
565	5. è†“ã™”çS»ææ,£è€...ã«ãšã‘ã,ã€ã^ãCE—ã...ç—æš•ã^ç™,æ³•. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 34, 267S-268S.		0
566	Immunosuppression in Pancreas Transplantation. , 2004, , 267-347.		3



#	ARTICLE	IF	CITATIONS
567	3. Tacrolimus. Japanese Journal of Clinical Pharmacology and Therapeutics, 2005, 36, 58-62.	0.1	0
568	Survey on Prescription Changes in Patients Following Renal Transplantation. Iryo Yakugaku (Japanese) Tj ETQq1 1 0,784314 rgBT /Ov	0.0	0
569	TRANSPLANT MEDICINE. , 2009, , 1269-1294.		0
570	Genotype-Guided Immunosuppression after Liver Transplantation: Chance for Individualizing Therapy?. Journal of Liver, 2012, 01, .	0.3	0
571	Emerging Role of Pharmacogenetic in Organ Transplantation. Journal of Transplantation Technologies & Research, 2012, 02, .	0.1	0
572	A Case Report of Kidney Graft Failure after Duodenal Bypass Surgery. Korean Journal of Medicine, 2012, 83, 369.	0.1	0
574	Evaluation of the Effects of Tacrolimus According to the Adjustment of Dosage Conversion Ratio in Switching from Intravenous to Oral Administration. Journal of Korean Society of Health-System Pharmacists, 2013, 30, 330-342.	0.1	0
576	Drug-Loss in Ingestion of Powdered-Form Tacrolimus, Related to Therapeutic Drug Monitoring.. Japanese Journal of Hospital Pharmacy, 1999, 25, 422-427.	0.0	1
577	<b>Application of Genotyping and Gene-Expression on Personalized Immunosuppressive Therapy in Liver Transplant Patients</b>. Japanese Journal of Clinical Pharmacology and Therapeutics, 2015, 46, 43-49.	0.1	0
578	Using the Logistic Regression to Predict Saudiâ€™s Kidney Transplant Rejection Patients. Biometrics & Biostatistics International Journal, 2017, 5, .	0.2	0
579	Population pharmacokinetics of tacrolimus in pediatric patients with systemicâ€™onset juvenile idiopathic arthritis: Initial dosage recommendations. Experimental and Therapeutic Medicine, 2019, 18, 4653-4660.	0.8	1
580	MÃ©dicaments du rejet de greffe. , 2020, , 79-88.		0
581	Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 183-193.	0.3	2
582	Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on realâ€™world data. Experimental and Therapeutic Medicine, 2020, 20, 1423-1430.	0.8	5
583	Availability of oral liquid formulations: Dilemmas in managing children with nephrotic syndrome. International Journal of Noncommunicable Diseases, 2020, 5, 194.	0.4	0
584	Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Xenobiotica, 2006, 36, 1-13.	0.5	9
585	Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. Transplant International, 2004, 17, 643-646.	0.8	1
586	Effects of antifungal drugs on the plasma concentrations and dosage of tacrolimus in kidney transplant patients. European Journal of Hospital Pharmacy, 2022, 29, 202-206.	0.5	5

#	ARTICLE	IF	CITATIONS
587	A review on therapeutic drug monitoring of immunosuppressant drugs. Iranian Journal of Basic Medical Sciences, 2011, 14, 485-98.	1.0	35
588	Success using tacrolimus in patients with proliferative and membranous lupus nephritis and refractory proteinuria. Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health, 2013, 72, 18-23.	0.4	8
589	Clinical outcomes after conversion from brand-name tacrolimus (prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study. P and T, 2013, 38, 484-8.	1.0	9
590	Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. Iranian Journal of Pharmaceutical Research, 2014, 13, 279-82.	0.3	0
591	Variations in Practice to Therapeutic Monitoring of Tacrolimus following Primary Adult Liver Transplantation. International Journal of Organ Transplantation Medicine, 2016, 7, 1-8.	0.5	21
592	The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. Yale Journal of Biology and Medicine, 2016, 89, 375-382.	0.2	78
593	Tacrolimus Dose Requirement in Iranian Kidney Transplant Recipients within the First Three Weeks after Transplantation. International Journal of Organ Transplantation Medicine, 2016, 7, 167-171.	0.5	0
594	Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?. Pharmaceutics, 2021, 13, 1960.	2.0	2
595	Predictive Performance of Published Tacrolimus Population Pharmacokinetic Models in Thai Kidney Transplant Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 105-116.	0.6	1
596	Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis. Pharmaceutics, 2022, 14, 261.	2.0	8
597	An alginate-based encapsulation system for delivery of therapeutic cells to the CNS. RSC Advances, 2022, 12, 4005-4015.	1.7	9
598	Current advances in colloidal based delivery systems for Tacrolimus. Journal of Drug Delivery Science and Technology, 2022, 68, 103108.	1.4	4
599	Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation. Clinical Biochemistry, 2022, 101, 9-15.	0.8	9
600	Prediction of Tacrolimus Dose/Weight-Adjusted Trough Concentration in Pediatric Refractory Nephrotic Syndrome: A Machine Learning Approach. Pharmacogenomics and Personalized Medicine, 2022, Volume 15, 143-155.	0.4	3
601	Plant-Derived Nanoscale-Encapsulated Antioxidants for Oral and Topical Uses: A Brief Review. International Journal of Molecular Sciences, 2022, 23, 3638.	1.8	4
602	Mechanism of cell death pathways in status epilepticus and related therapeutic agents. Biomedicine and Pharmacotherapy, 2022, 149, 112875.	2.5	14
603	Estimation of the Pharmacokinetic Parameters of the Anti-rejection Drugs in Lung Transplantation. , 2021, , .		1
604	Dysbiosis of Ocular Surface Microbiota in Patients With Refractive Allergic Conjunctival Diseases. Cornea, 2022, 41, 1232-1241.	0.9	4

#	ARTICLE	IF	CITATIONS
605	Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. <i>BMC Gastroenterology</i> , 2021, 21, 494.	0.8	0
606	The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern- West, Iran. <i>Advanced Pharmaceutical Bulletin</i> , 2022, , .	0.6	0
610	The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2022, , .	0.8	1
611	Recommendations for IVDR compliant in-house software development in clinical practice: a how-to paper with three use cases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 982-988.	1.4	8
613	Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2023, 45, 95-101.	1.0	2
614	Rectal INdomethacin, oral TacROlimus, or their combination for the prevention of post-ERCP pancreatitis (INTRO Trial): Protocol for a randomized, controlled, double-blinded trial. <i>Pancreatology</i> , 2022, 22, 887-893.	0.5	1
615	A review of the rationale for the testing of the calcineurin inhibitor tacrolimus for post-ERCP pancreatitis prevention. <i>Pancreatology</i> , 2022, 22, 678-682.	0.5	2
616	Pharmacokinetic Model Based on Stochastic Simulation and Estimation for Therapeutic Drug Monitoring of Tacrolimus in Korean Adult Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 729-737.	1.0	2
617	Sotorasib associated with tacrolimus and everolimus: A significant drug interaction in lung transplant patients. <i>Transplant Immunology</i> , 2022, 74, 101678.	0.6	1
618	Explainability methods for machine learning systems for multimodal medical datasets. , 2022, , .		1
619	Donor and Recipient Polymorphisms of MAPK Signaling Pathway Genes Influence Post-Transplant Liver Function in Chinese Liver Transplant Patients Taking Tacrolimus. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
620	Predicting Tacrolimus Exposure in Kidney Transplanted Patients Using Machine Learning. , 2022, , .		2
621	Compare the performance of multiple machine learning models in predicting tacrolimus concentration for infant patients with living donor liver transplantation. <i>Pediatric Transplantation</i> , 2023, 27, .	0.5	4
622	Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	2
623	P-glycoprotein, FK-binding Protein-12, and the Intracellular Tacrolimus Concentration in T-lymphocytes and Monocytes of Kidney Transplant Recipients. <i>Transplantation</i> , 2023, 107, 382-391.	0.5	6
625	Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2022, 8, .	0.4	6
626	Comparative Study of 2 Extended-Release Tacrolimus Formulations in Kidney Transplantation. <i>Transplantation Proceedings</i> , 2022, 54, 2434-2438.	0.3	0
627	Milk-alkali syndrome and Tacrolimus Metabolism. <i>Transplantation Reports</i> , 2022, , 100123.	0.3	1

#	ARTICLE	IF	CITATIONS
629	Tiempo entre el Uso de Tacrolimo y el Nivel S�rico Objetivo en Pacientes Despu�s de un Trasplante Hep�tico en Adultos. Brazilian Journal of Transplantation, 2022, 25, .	0.1	0
630	Time Between Start of Tacrolimus Use and Target Serum Level in Patients After Adult Liver Transplantation. Brazilian Journal of Transplantation, 2022, 25, .	0.1	0
631	Tempo entre In�cio do Uso de Tacrolimo e N�vel Sangu�neo Alvo em Pacientes P�s-Transplante Hep�tico Adulto. Brazilian Journal of Transplantation, 2022, 25, .	0.1	0
632	Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus. Gene, 2023, 857, 147190.	1.0	0
633	Population PK / PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients. CPT: Pharmacometrics and Systems Pharmacology, 0, , .	1.3	0
634	Individual dose recommendations for drug interaction between tacrolimus and voriconazole in adult liver transplant recipients: A semiphysiologically based population pharmacokinetic modeling approach. European Journal of Pharmaceutical Sciences, 2023, 184, 106405.	1.9	4
635	Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP�tacrolimus conversion ratios. Clinical Transplantation, 2023, 37, .	0.8	0
636	Physiologically based pharmacokinetic modeling of tacrolimus for food‐drug and CYP3A drug‐gene interaction predictions. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 724-738.	1.3	2
637	Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP�Tacrolimus. Clinical Transplantation, 0, , .	0.8	0
638	Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation. Pharmacogenetics and Genomics, 2023, 33, 59-65.	0.7	0
639	Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents. Journal of the American Society of Nephrology: JASN, 2023, 34, 1069-1077.	3.0	5
640	A Multi-Centre Non-Interventional Study to Assess the Tolerability and Effectiveness of Extended-Release Tacrolimus (LCPT) in De Novo Liver Transplant Patients. Journal of Clinical Medicine, 2023, 12, 2537.	1.0	1
641	Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation. Journal of Personalized Medicine, 2023, 13, 656.	1.1	1
645	Pharmacogenomics of immunosuppressants. , 2023, , 323-344.		0
663	Pharmacogenomics on Immunosuppressive Drugs in Solid Organ Transplantation. , 2023, , 263-270.		0
671	Post-Heart Transplant Care and Long-Term Complications in Children. , 2023, , 1-40.		0